ProCE Banner Activity

Interim Results From the Phase III Northstar-3 (HGB-212) Study of Betibeglogene Autotemcel in Patients With Severe Transfusion-Dependent β-Thalassemia

Slideset Download
Conference Coverage
Interim results from the phase III Northstar-3 study showed that most patients with transfusion-dependent β-thalassemia who received betibeglogene autotemcel gene therapy produced sufficient HbAT87Q to stop RBC transfusions for ≥ 3 months.

Released: December 17, 2019

Expiration: December 15, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company